VIR stock icon

Vir Biotechnology
VIR

$10.48
0.01%
 

About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Employees: 587

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 12 analysts
0
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 66

2% more capital invested

Capital invested by funds: $887M [Q4 2023] → $904M (+$16.9M) [Q1 2024]

0.5% more ownership

Funds ownership: 65.52% [Q4 2023] → 66.03% (+0.5%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

0% less funds holding

Funds holding: 201 [Q4 2023] → 200 (-1) [Q1 2024]

3% less call options, than puts

Call options by funds: $1.79M | Put options by funds: $1.85M

3% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 31

Research analyst outlook

12 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
14%
downside
Avg. target
$60
469%
upside
High target
$110
950%
upside

12 analyst ratings

positive
67%
neutral
33%
negative
0%
Morgan Stanley
Michelle Gilson
43%upside
$15
Equal-Weight
Maintained
6 Jun 2024
HC Wainwright & Co.
Patrick Trucchio
950%upside
$110
Buy
Reiterated
5 Jun 2024
Needham
Joseph Stringer
81%upside
$19
Buy
Maintained
5 Jun 2024
HC Wainwright & Co.
Patrick Trucchio
950%upside
$110
Buy
Reiterated
24 May 2024
HC Wainwright & Co.
Patrick Trucchio
950%upside
$110
Buy
Reiterated
7 May 2024

Financial journalist opinion

Based on 8 articles about VIR published over the past 30 days